Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NRIX
stocks logo

NRIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
13.41M
+0.98%
-0.916
+22.13%
16.72M
-9.4%
-0.843
+25.75%
17.50M
-60.28%
-0.849
+63.22%
Estimates Revision
The market is revising Downward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by -6.77% over the past three months. During the same period, the stock price has changed by 81.84%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.77%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.83%
In Past 3 Month
Stock Price
Go Up
up Image
+81.84%
In Past 3 Month
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 24.93 USD with a low forecast of 12.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 24.93 USD with a low forecast of 12.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 18.020
sliders
Low
12.00
Averages
24.93
High
33.00
Current: 18.020
sliders
Low
12.00
Averages
24.93
High
33.00
Truist
NULL -> Buy
initiated
$23 -> $30
2025-11-24
Reason
Truist
Price Target
$23 -> $30
2025-11-24
initiated
NULL -> Buy
Reason
Truist assumed coverage of Nurix Therapeutics with a Buy rating with a price target of $30, up from $23. The firm sees the company's bexo's clinical data and pivotal trial start in CLL - chronic lymphocytic leukemia - as a meaningful proof-of-concept for Nurix's protein degradation platform, the analyst tells investors in a research note. Truist adds that the combination of a de-risked lead program in hem-onc and the broad optionality and catalyst path in I&I - inflammation and immunology - are the central pillars of its investment thesis for the stock.
JPMorgan
Tessa Romero
Overweight
downgrade
$30 -> $22
2025-11-18
Reason
JPMorgan
Tessa Romero
Price Target
$30 -> $22
2025-11-18
downgrade
Overweight
Reason
JPMorgan analyst Tessa Romero lowered the firm's price target on Nurix Therapeutics to $22 from $30 and keeps an Overweight rating on the shares following a transfer of coverage. The firm views Nurix as a "differentiated name" within the emerging oral target protein degrader space.
H.C. Wainwright
Buy
downgrade
$33 -> $28
2025-10-28
Reason
H.C. Wainwright
Price Target
$33 -> $28
2025-10-28
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Nurix Therapeutics to $28 from $33 and keeps a Buy rating on the shares. The firm cites the company's equity financing for the target drop.
Wells Fargo
Overweight
downgrade
$22 -> $21
2025-10-23
Reason
Wells Fargo
Price Target
$22 -> $21
2025-10-23
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Nurix Therapeutics (NRIX) to $21 from $22 and keeps an Overweight rating on the shares. The firm thinks the clarity on bexdeg's 3L+ CLL pivotal trial dose plus concurrent financing removes key overhangs. With the company funded into 2028, read through from Kymera Therapeutics' (KYMR) upcoming KT-621 Phase 1b data and a potential GILD IRAK4 opt-in decision in 2026, Wells likes the setup.
BTIG
Buy
downgrade
$35 -> $27
2025-10-23
Reason
BTIG
Price Target
$35 -> $27
2025-10-23
downgrade
Buy
Reason
BTIG lowered the firm's price target on Nurix Therapeutics to $27 from $35 and keeps a Buy rating on the shares. The firm cites the company having detailed their pivotal plans for bexobrutideg in r/r CLL - Relapsed or Refractory Chronic Lymphocytic Leukemia - and announced a concurrent raise of $250M, noting that the raise clears a financing overhang for the stock and providing a line of sight to key data catalysts and accelerating bexdeg's I&I expansion, the analyst tells investors in a research note.
RBC Capital
Gregory Renza
Outperform
maintain
$28 -> $29
2025-10-22
Reason
RBC Capital
Gregory Renza
Price Target
$28 -> $29
2025-10-22
maintain
Outperform
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $29 from $28 and keeps an Outperform rating on the shares. The firm notes that the pivotal study initiation and pipeline updates are positive developments that should pave the way for bex-deg's initial late-line CLL opportunity while the company gears up to initiate its 2L+ confirmatory study in the first half of 2026. RBC continues to believe bex-deg has shown a competitive profile to date and with potential for more supportive data at ASH, and with meaningful optionality in exciting I&I collaborations that data from other companies' programs could have positive read-throughs towards, it sees shares as undervalued given the large opportunities with their degrader platform.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nurix Therapeutics Inc (NRIX.O) is -4.82, compared to its 5-year average forward P/E of -5.92. For a more detailed relative valuation and DCF analysis to assess Nurix Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.92
Current PE
-4.82
Overvalued PE
-2.24
Undervalued PE
-9.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.53
Undervalued EV/EBITDA
-6.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.11
Current PS
0.00
Overvalued PS
29.82
Undervalued PS
6.40
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 418.49% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 418.49% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NRIX News & Events

Events Timeline

(ET)
2025-11-10
07:42:44
Nurix Therapeutics Names Dansey to Board of Directors
select
2025-11-07 (ET)
2025-11-07
09:12:17
Nurix Therapeutics Reveals New Data Presentation on NX-1607
select
2025-10-22 (ET)
2025-10-22
07:24:22
Nurix sets price for 24.5 million shares at $10.21 in underwritten registered offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-01Globenewswire
Nurix Therapeutics to Host Webcast on December 8 to Review BTK Degrader Clinical Data
  • Clinical Data Update: Nurix Therapeutics will host a webcast on December 8, 2025, to present updated clinical data on its BTK degrader, bexobrutideg, aiming to enhance investor understanding of the company's R&D progress and bolster market confidence.
  • Expert Participation: The webcast will feature guest speaker Dr. Alvaro Alencar from the University of Miami Sylvester Cancer Center, who will share clinical trial data on bexobrutideg in patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia, further validating the drug's clinical efficacy.
  • Clinical Trial Progress: Bexobrutideg is currently undergoing the NX-5948-301 Phase 1a/1b clinical trial, evaluating its efficacy in patients with relapsed or refractory B-cell malignancies, which is expected to provide critical data support for the company's future drug development.
  • Corporate Strategy Update: Nurix's CEO Arthur T. Sands and CMO Paula G. O’Connor will discuss the company's clinical development strategy during the webcast, showcasing its innovative capabilities in targeted protein degradation, aiming to attract more investor interest in its potential market opportunities.
[object Object]
Preview
5.0
11-10Newsfilter
Nurix Therapeutics Welcomes Esteemed Biopharmaceutical Executive Roger Dansey, M.D., to Its Board of Directors

  • Appointment of Dr. Roger Dansey: Nurix Therapeutics has appointed Dr. Roger Dansey, a seasoned expert in oncology with extensive leadership experience, to its board of directors to enhance its strategic direction in drug development.

  • Focus on Targeted Protein Degradation: Nurix is pioneering targeted protein degradation medicines aimed at treating cancer and autoimmune diseases, with a clinical pipeline that includes innovative therapies like bexobrutideg for chronic lymphocytic leukemia.

  • Dr. Dansey's Background: Dr. Dansey has held significant roles in major pharmaceutical companies, including Pfizer and Seagen, and has contributed to the development of several breakthrough cancer therapies, bringing valuable expertise to Nurix.

  • Company's Vision and Pipeline: Nurix aims to revolutionize drug discovery with its AI-integrated platform and has a robust pipeline of clinical and preclinical candidates, including collaborations with major pharmaceutical companies for co-development and commercialization.

[object Object]
Preview
9.0
11-07Newsfilter
Nurix Therapeutics Unveils New Translational Findings from First Human Clinical Trial of Oral CBL-B Inhibitor NX-1607, Highlighting Immune Activation and Tumor Microenvironment Changes

  • NX-1607 Presentation: Nurix Therapeutics presented new data on NX-1607, a first-in-class oral CBL-B inhibitor, at the SITC 2025 Annual Meeting, highlighting its potential in treating advanced solid tumors through immune modulation.

  • Clinical Findings: The data showed dose-dependent pharmacologic activity and increased T cell activation in patients with stable disease, suggesting a link between immune activation and tumor control.

  • Case Study Insights: A case study of a patient with metastatic castration-resistant prostate cancer demonstrated that NX-1607 treatment led to stable disease and significant immune activation within the tumor microenvironment.

  • Future Development: The findings support the continued development of NX-1607 as a novel checkpoint inhibitor therapy, with potential applications as a monotherapy and in combination with other cancer treatments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nurix Therapeutics Inc (NRIX) stock price today?

The current price of NRIX is 18.02 USD — it has increased 7.07 % in the last trading day.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s business?

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

arrow icon

What is the price predicton of NRIX Stock?

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 24.93 USD with a low forecast of 12.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s revenue for the last quarter?

Nurix Therapeutics Inc revenue for the last quarter amounts to 7.89M USD, decreased -37.29 % YoY.

arrow icon

What is Nurix Therapeutics Inc (NRIX)'s earnings per share (EPS) for the last quarter?

Nurix Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, increased 53.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nurix Therapeutics Inc (NRIX)'s fundamentals?

The market is revising Downward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by -6.77% over the past three months. During the same period, the stock price has changed by 81.84%.
arrow icon

How many employees does Nurix Therapeutics Inc (NRIX). have?

Nurix Therapeutics Inc (NRIX) has 286 emplpoyees as of December 05 2025.

arrow icon

What is Nurix Therapeutics Inc (NRIX) market cap?

Today NRIX has the market capitalization of 1.83B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free